A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the …
M Oosterveld, S Suciu, P Muus, M Delforge, A Belhabri… - Blood, 2004 - Elsevier
The use of intensive antileukemic treatment is less widely accepted in high-risk MDS pts
compared to de novo AML, due to the reported inferior results. It is questionable whether the …
compared to de novo AML, due to the reported inferior results. It is questionable whether the …
[HTML][HTML] The Prognosis of Intermediate-and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to …
M Hong, Q Sun, W Liu, H Zhu, Y Zhu, J Li, S Qian - Blood, 2021 - Elsevier
Introduction: AML is an extremely heterogenous disease which poses fundamental
challenges in developing effective treatment regimens, while simultaneously highlighting the …
challenges in developing effective treatment regimens, while simultaneously highlighting the …
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive …
M Oosterveld, S Suciu, P Muus, U Germing… - Annals of …, 2015 - Springer
High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome
after intensive treatment compared with de novo acute myeloid leukemia (AML) patients …
after intensive treatment compared with de novo acute myeloid leukemia (AML) patients …
Intensive chemotherapy in de novo MDS. Outcome of patients who achieved partial remission (PR)
E Wattel, S Debotton, M Hebbar, A Merlat, F Bauters… - Leukemia …, 1997 - elibrary.ru
Intensive anthracycline-AraC chemotherapy (IC), in MDS, gives lower complete remission
(CR) rates than in de novo AML. Patients who survive the period of aplasia and do not …
(CR) rates than in de novo AML. Patients who survive the period of aplasia and do not …
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense'induction regimens: a report from SWOG and MD Anderson
M Othus, H Kantarjian, S Petersdorf, F Ravandi… - Leukemia, 2014 - nature.com
Less-intense remission induction regimens for adults with newly diagnosed acute myeloid
leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death …
leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death …
Recent developments in the prognostic classification for MDS: results of the international risk analysis workshop
P Greenberg, C Cox, M LeBeau, P Fenaux, P Morel… - Leukemia …, 1997 - elibrary.ru
The International MDS Risk Analysis Workshop combined cytogenetic, morphologic and
clinical data which were collated and analyzed centrally from 816 patients with untreated …
clinical data which were collated and analyzed centrally from 816 patients with untreated …
Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.
K Wheatley, CL Brookes, RK Hills, AH Goldstone… - 2005 - ashpublications.org
AML is a heterogeneous disease and several prognostic factors are well established in
younger patients. Less work has been done on parameters affecting outcome in older …
younger patients. Less work has been done on parameters affecting outcome in older …
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group
Y Morita, A Kanamaru, Y Miyazaki, D Imanishi… - International journal of …, 2010 - Springer
A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed
from MDS (MDS–AML) were registered in a randomized controlled study of the Japan Adult …
from MDS (MDS–AML) were registered in a randomized controlled study of the Japan Adult …
Impact of Post-Remission Therapy on Survival of Older Patients with AML Treated with Intensive Chemotherapy: Results of the Multicenter ALFA-9803 Trial.
P Turlure, C Gardin, JV Malfuson, X Thomas, C Terre… - 2006 - ashpublications.org
Background: More than 50% of newly-diagnosed patients with AML are older than 60 years
of age. In this age group, the benefits of intensive chemotherapy are debated, due to …
of age. In this age group, the benefits of intensive chemotherapy are debated, due to …
Post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger AML patients: long-term follow-up results …
F Baron, F Efficace, L Cannella, F Mandelli, R Willemze… - 2016 - ashpublications.org
The 2 first authors contributed equally to the work. Background. The best post-remission
treatment for younger acute myeloid leukemia (AML) patients has remained controversial …
treatment for younger acute myeloid leukemia (AML) patients has remained controversial …